ArticleCell communication and signaling : CCS2023
FTO facilitates cancer metastasis by modifying the m
Article in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Lian-Jia-San-Jie formula suppresses non-small cell lung cancer via FTO-dependent mBiochemistry and biophysics reports · 2026Article
- N6-methyladenosine-mediated upregulation of PAICS promotes lung-adenocarcinoma metastasis via the integrin-FAK signaling.Oncogene · 2026Article
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Fibroblast Activation Protein Promotes Thoracic Aortic Dissection via PLAUR/ITGB1-Mediated Pro-inflammatory Macrophage Polarization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Reader-dependent functional duality of FTO: a context-switching node at the intersection of immune evasion and therapeutic resistance.Frontiers in immunology · 2026Review
- The role of m6A modification in non-small cell lung cancer: functional insights and impact on therapy resistance.Cancer cell international · 2025Review
- Enhanced multi-omics analysis reveals a lncRNA signature with 12 RNA modifications to predict tumor heterogeneity and potential therapy in non-small cell lung cancer.Discover oncology · 2025Article
- The Role of Fat Mass and Obesity-Associated (FTO) Gene in Non-Small Cell Lung Cancer Tumorigenicity and EGFR Tyrosine Kinase Inhibitor Resistance.Biomedicines · 2025Article
- Mechanistic and therapeutic insights into the function of N6-methyladenosine in arthritic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- The role of N(6)-methyladenosine (m6a) modification in cancer: recent advances and future directions.EXCLI journal · 2025Review
- The m6A demethylase FTO suppresses glioma proliferation by regulating the EREG/PI3K/Akt signaling pathway.Frontiers in cell and developmental biology · 2025Article
- Targeting FAP-positive chondrocytes in osteoarthritis: a novel lipid nanoparticle siRNA approach to mitigate cartilage degeneration.Journal of nanobiotechnology · 2024Article
- Medicinal chemistry aspects of fat mass and obesity associated protein: structure, function and inhibitors.Future medicinal chemistry · 2024Review
- NCellular & molecular biology letters · 2024Article
- The role of m6A methylation in targeted therapy resistance in lung cancer.American journal of cancer research · 2024Review
- M6A Methylation Regulators METTL3 and ALKBH5 are Risk Factors for EGFR-Mutant NSCLC.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests the critical roles of N
methodsA human m
resultsFTO was upregulated and predicted poor prognosis in patients with NSCLC. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m
conclusionOur current findings provided valuable insights into the role of FTO-mediated m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.